Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA1 | P00915 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458085 | 0.82 | CA12 (1.00) | CA12CA1CA9GLAKMT2A | |
| SCHEMBL11114613 | 0.80 | ADAM17 (0.48) | CA12CA1CA9GLAADAM17 | |
| SCHEMBL27893066 | 0.80 | CA12 (0.69) | CA12CA1CA9GLAKMT2A | |
| SCHEMBL11478927 | 0.80 | CA12 (0.67) | CA12CA1CA9GLAKMT2A | |
| SCHEMBL2951693 | 0.79 | ALDH1A1 (0.63) | CA12CA1CA9GLAKMT2A | |
| SCHEMBL10082605 | 0.78 | ALDH1A1 (0.60) | CA1CA9KMT2APOLBMEN1 | |
| SCHEMBL16925630 | 0.78 | CA9 (0.56) | CA12CA1CA9GLAKMT2A | |
| SCHEMBL371252 | 0.78 | DDAH1 (0.68) | ADAM17KMT2AALDH1A1 | |
| SCHEMBL25676620 | 0.77 | ALDH1A1 (0.59) | ADAM17KMT2AALDH1A1L3MBTL1NPC1 | |
| SCHEMBL12261669 | 0.77 | CA12 (0.70) | CA12CA1CA9GLAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583902-B | Preparation method of alkynyl thioether compound | 江苏医药职业学院 | 2024-02-13 | — | — | CN | disclosed |
| CN-115583902-A | Preparation method of alkynyl thioether compound | 江苏医药职业学院 | 2023-01-10 | — | — | CN | disclosed |
| EP-2261696-B1 | Copolymerizable azo compounds and articles containing them | ABBOTT MEDICAL OPTICS INC (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7994135-B2 | Monomethylvaline compounds capable of conjugation to ligands | SEATTLE GENETICS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-7807670-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-05 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | YOAKIM CHRISTIANE | 2010-02-18 | — | — | US | disclosed |
| US-7528167-B2 | Inhibitors of papilloma virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2009-05-05 | — | — | US | disclosed |
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | SEATTLE GENETICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7326423-B2 | Copolymerizable azo compounds and articles containing them | ADVANCED MEDICAL OPTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7326423-B2 | Copolymerizable azo compounds and articles containing them | ADVANCED MEDICAL OPTICS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1345943-B1 | INHIBITORS OF PAPILLOMA VIRUS | BOEHRINGER INGELHEIM CA LTD (CA) | 2007-03-21 | — | — | EP | disclosed |
| WO-1992017516-A1 | PROCESS FOR CURING POLYQUINOLINE POLYMERS AND COMPOSITIONS THEREOF | MAXDEM INCORPORATED (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047296-A1 | Antibodies conjugated to Auristatin analogs via a maleimidocaproyl lingages; for treating cancer, autoimmune diseases and infectious diseases | MMAB, CAD, TRIM59 | CA12 1279/4885CA1 1750/4885CA9 2039/4885 |
| US-20100041649-A1 | INHIBITORS OF PAPILLOMA VIRUS | REV1, CDKN1A, RB1 | CA12 1783/4885CA1 1965/4885CA9 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.